Darragh A, Gordon A J, O'Byrne H, Hobbs D, Casey E
Eur J Clin Pharmacol. 1985;28(3):305-9. doi: 10.1007/BF00543328.
Age-dependent changes in pharmacokinetics are considered a possible factor contributing to a higher risk of side-effects from drug treatment in the elderly. However, very little is known about the kinetics and metabolism of most NSAI agents in geriatric subjects. In a prospective age-comparison study, the single dose and steady-state pharmacokinetics of piroxicam 20 mg once daily were determined in 44 subjects ranging in age from 30 to 80 years. Plasma concentrations, elimination half-life, AUC, and volume of distribution were not influenced by age or sex and were in agreement with previously reported results in young adults. Pharmacokinetic parameters in 18 patients with evidence of mild or moderate renal impairment at study entry were not different from those in patients without impairment. Based on this and other studies, elderly patients receiving the recommended dose of piroxicam are not exposed to undue risk related to pharmacokinetic considerations.
药代动力学的年龄依赖性变化被认为是导致老年人药物治疗副作用风险较高的一个可能因素。然而，对于大多数非甾体抗炎药（NSAI）在老年受试者体内的动力学和代谢情况，人们了解甚少。在一项前瞻性年龄比较研究中，对44名年龄在30至80岁之间的受试者测定了每日一次服用20毫克吡罗昔康的单剂量和稳态药代动力学。血浆浓度、消除半衰期、曲线下面积（AUC）和分布容积不受年龄或性别的影响，与之前在年轻成年人中报道的结果一致。在研究开始时，18名有轻度或中度肾功能损害证据的患者的药代动力学参数与无肾功能损害的患者并无差异。基于此项研究及其他研究，接受推荐剂量吡罗昔康的老年患者不存在因药代动力学因素而面临的不当风险。
